N
Google TrendARSENAL (5000+) — Arsenal v Lille: Champions League – live
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:arsenal5000+anthony gordon500+montez sweat2000+rob lowe1000+tanner hudson500+frozen frenzy200+huevo1000+payton pritchard1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "REGENXBIO Reports Second" (30 stories)

Top Headline Story

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
Lead StoryPR Newswiregeneral
Aug 6

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxPblhrOHY5eU95SDJZYnZoemREeWltUmxEM3Mwb1ZaM0dFYjhoR25lTmstMzhmRDhkbXJBbFRYckJsRzF2M3F6bTRLYVAtcGhxSmZuMTZ5RHZrTUJMQWM5SDlLM1piMFRVWExPOC15Wks2QzdGMlUzWS1fT0xGLU84V3pxTU03VmNSLWdXbWFuS3JKSmdZU011NkVUc1lwVkp1c1hsTTE1QmF4NzJDYWNKTnhkWXhSWHpEVm9BSDR6LXppeW1PZW53U3o0OWpqaFlXSm42VA?oc=5" target="_blank">REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+23m ago

arsenal

Arsenal v Lille: Champions League – live

Filter stories
500+23m ago

anthony gordon

Anthony Gordon's first Barcelona goal, Manuel Neuer's mistake and Djed Spence's Inter debut in the Euro Debrief

Filter stories
2000+33m ago

montez sweat

Bears DE Montez Sweat suspended two games for violating NFL's PED policy

Filter stories
1000+43m ago

rob lowe

Ben Shapiro’s Star-Studded ‘Confession’ Film Includes James Franco, Rob Lowe And More

Filter stories

Search Results for "REGENXBIO Reports Second"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Six of 10 study participants had better diabetic eye-disease scores three years after one treatment.
Stock Titangeneral

Six of 10 study participants had better diabetic eye-disease scores three years after one treatment.

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQNk1yNGhNckxxd2pNQ3M2a3VLb2QwM2pkZlNTSTRvLVRBazVoMjhSYTBpLVJRcDRjNlJ1amdqdDZWOUpBVGlocTZFTU9ZNUxKVy1CVXJBSmlZOEdWZ2dXSWJGNUdzMk5oMHNPaGtBcnJjTElxRm04WENvQVZmakZMYXUxWHhFemVVZ1g4WGNjVlZOdVVheGI2M0pIdHpZX21kUWNMaHVQQk5helJNZlVBaS1FZ3IySHdxcVNZaWV5bEs?oc=5" target="_blank">Six of 10 study participants had better diabetic eye-disease scores three years after one treatment.</a>  <font color="#6f6f6f">Stock Titan</font>

Read Full StoryMore like this
REGENXBIO reports three-year ALTITUDE DRSS data
Mugglehead Investment Magazinegeneral

REGENXBIO reports three-year ALTITUDE DRSS data

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9iMmlHal9CMlFId01KbVdSRkxiT0NSXy03bVBrcFJRQ2k5cmVSUG9PYldLM0Z6MEZZSEJGbldxd0R3T01WR2FQalRoREhrbGtRdkNNNmJxZ3FmMndoRGgyaGZvSnlBUVFFYmRuanJNaHNnQmg4OGV4MHNn?oc=5" target="_blank">REGENXBIO reports three-year ALTITUDE DRSS data</a>  <font color="#6f6f6f">Mugglehead Investment Magazine</font>

Read Full StoryMore like this
REGENXBIO Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
marketscreener.comworld

REGENXBIO Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxPV24xWHNvd3dJWWdrTlFPcVZOUmJBam9hWmt5dFFOQ2laMlVxbHU2dnFQNDVGN0xlR1Y1SzhkeHNVRHEyNU53anJiS0pIOElpSmxacTgwRFhhMDdMc3hvN3lOeV8tZVdCWEh5eUo3VGFTay1Ra3FRWkx2WFNfX0M3YTlENkI2WkFuOVhraWo4aW1kODJDV1huNW8xNEpwYWtfclRqTUdOM0M3NjliT0FHSzV1SzYzQ2xldm5paEQtdXhDeS1KNjBnNS1tWEsxWV9wNTNvbFdPel9OU3ctVDZsakpR?oc=5" target="_blank">REGENXBIO Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026</a>  <font color="#6f6f6f">marketscreener.com</font>

Read Full StoryMore like this
Regenxbio’s Second Clinical Hold in Eight Months Exposes a Safety Monitoring System That Was Never Rebuilt After the First One
The Clinical Trial Vanguardgeneral

Regenxbio’s Second Clinical Hold in Eight Months Exposes a Safety Monitoring System That Was Never Rebuilt After the First One

<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxOdHhoLW5ESUx5QXBWcHZPeGl3bjM0OGRPcXktb2xYWGs3ZDl5SEZtbDdOUXZ4M01UZGszMWZXdFRyY2UyeURLYk53M3F1V3VFSnBLdVk4TGxjSDlDNVh0SHc1U0E5SUVVY1NnZEhCcDBrNGcwUUx6ZWo4YkRWUjFxeE03Y3otNHJSQmFEcXdvWk1GZ2tJVVJGTFh1LU1JaG1JY2UxV2kwME5CY3pOV0NvWlFUX2hWYnJIWUlaRWh6b09MbWZiUWxYenlOZFNCWVN2OEpSZWd4NWtwNVU3QVM3cF84dVdabVdTSlNNWFBzdk1oZnVOWG9xUi1kN2NQN2kxMmI2Y2ZtZ3hqb054a1E?oc=5" target="_blank">Regenxbio’s Second Clinical Hold in Eight Months Exposes a Safety Monitoring System That Was Never Rebuilt After the First One</a>  <font color="#6f6f6f">The Clinical Trial Vanguard</font>

Read Full StoryMore like this
StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate
Genetic Engineering and Biotechnology Newsmarkets

StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPZkp0VzdkNVVCV0NTejgyeUs5emJBczlDcmZNRDZaSzQ2YXFuQ1diNnpLSE9oMmY0UHZSNllUY25rX0huN3ZNZEZUY2JUUDZ2Y2NCczJ1MlJLZ2RNVDU3OU1TM3RmVjhmQWxlcXppM3FpVFltTmxKTkxuWU8waVRON01IOTJoSHlLSW1BMDFvNjItZDVmTjF3N29MVmpaQlpyY0ZVUHdFSWhuTGtLNFY4RlFnVUFMaHItbEtpZzJHV1BkT1B5bVBmSmdwYmtxbmJTZ2RPTkoyRm01Y2hxUkE4Qg?oc=5" target="_blank">StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate</a>  <font color="#6f6f6f">Genetic Engineering and Biotechnology News</font>

Read Full StoryMore like this
Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says
WSJgeneral

Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOc2N2cW5RczhjMXdrS2VOMEppMW5xZGVfT1pqZnlFeGNybDJFQnNLRHA0YlFDS3RFLVNjYjhXS291SG1NaWwtbUlUSFhTZEFVT3hhNm9hRFRkUUR4dGtXcjhyV3pYbS1YY29KUjVjR0xRUTVjVGYwbzlWR2hKcDZpS0NXTHItWEplZGs2TUUyeEtCcFhSNmlxeDRIeFJwS0xKUndIX2syc2t4OTBMUmUw?oc=5" target="_blank">Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says</a>  <font color="#6f6f6f">WSJ</font>

Read Full StoryMore like this
Earnings call transcript: REGENXBIO beats on Q2 2026 EPS, shares rise premarket
Investing.commarkets

Earnings call transcript: REGENXBIO beats on Q2 2026 EPS, shares rise premarket

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOdUl0SzhEZ05IdmtnUUllZjB5SlRURkM4RnF5NXZ6YkV2WmJkN2lTcWZkdkJNcTNVQVZ4MkpPbHZIR1FYUmUzQ0t1elRveFZlcmZaZ2l2SUFDLXpQejJoTFRjVmltOG5YS2dsd3lXOWF5MWw4THl5TjZlTWVqSW45aVIyVmozS1oxRkt2WHdCNVpxU1c2V0JrR3lhRE9tTmItN0FqQzAya0V0TTBMMDNMSWFpSkdoY3F6NFN3ZnhUQ2VsalNHTEpuUWx5TjkyQQ?oc=5" target="_blank">Earnings call transcript: REGENXBIO beats on Q2 2026 EPS, shares rise premarket</a>  <font color="#6f6f6f">Investing.com</font>

Read Full StoryMore like this
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
PR Newswiregeneral

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPTHh6Uzk2bXgxMVRRSTBEX0dmMG9ORmR2X1BiVThBMU41a091LWlrdkJfT09QMUlvMm96TGJCNVgtQUlwanZfbFdubnF2VktnTWZMc3NTaFUwSTJPdnJucXB5eW5FS1V2TTRoZWZJUlFBb0hYczF0SnlkbXFiV3R6emxzeWFRRXRvUjUwUlFXOWxPRTB6Yk42SE93QVp4VnZ0Y1dnSzBzYTIzekJmTWZSd0lMN3l4VHh0VGhtNS1OTm0xWFBFcDFILWVubW1hTXYzamtn?oc=5" target="_blank">REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies
BioSpacegeneral

REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOamphSGV1MWJvOE5JWU1SNG5FWjNMbVFMNWhmZnhoOUJabTMzeXZPOW1Bc0JmWnp0VTd4ZGx3OEUxSUs2eGtFUUxzZGNDLWVMN3ZqTGhnc042YjN1MXlXR2hKb3RUX0hpa0ZzMFhZTnJzVzlYTTJmX0xjVXRheDNQZW05TFRUOUJ2WnVDSERxOWZsUGJEbmw1UFktNDdIUTB3UzFHZ2lzOGwyaW1NVk40?oc=5" target="_blank">REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
REGENXBIO stock reports durable gene therapy data from Phase II
AD HOC NEWSmarkets

REGENXBIO stock reports durable gene therapy data from Phase II

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNbW1tc3VZalRjdk51WHFTM1Z4LVZScmY2NWFWenAzdmRJNm1OZDlJZE01eHRSUTcxUGYtMkFfd0lwQU1KMG1WcUstVmFrWW9sZU1nLTAxeXdRQWtMQ3RFUXpNRjlFVjJ5eU9Ja2FGUVRvZmtVNFdkVTRhbXdfbkJ2d1N5dE5NbFZhMEpjQ3ZUaG9YNUotZnhCWWluR2RneTI5MGxMQ1RiRWtQaHNBX2dkNjZhbldOSHhyZ1FNQmNNNXJnWVdM?oc=5" target="_blank">REGENXBIO stock reports durable gene therapy data from Phase II</a>  <font color="#6f6f6f">AD HOC NEWS</font>

Read Full StoryMore like this
Regenxbio posts clean safety profile for DMD gene therapy as pivotal data loom
Fierce Biotechgeneral

Regenxbio posts clean safety profile for DMD gene therapy as pivotal data loom

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNaWF5eEV0TzdWLXV6Q0ZVTG1RT2pxSTZHTlJhUm9MM0MybVRqWEg4Wk9JQzdGV2pGb25zUE1nQzJoV0s0QV96T2hBd0pjZnNjQWwwb0xzS3gybTVHOEhodDUySVZQSWtlVjB1TUdXaGlvOTlJTTRBeVBRSzNGWnVmOXZmam5vc1JxZUxPMDBEYU5OYzRoNEdKSzNSRkVJcUZ6NXU0bEV1dXdPQV9ZZEE?oc=5" target="_blank">Regenxbio posts clean safety profile for DMD gene therapy as pivotal data loom</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
FDA Slams REGENXBIO's MPS II Gene Therapy RGX-121 With CRL
CGTLive®general

FDA Slams REGENXBIO's MPS II Gene Therapy RGX-121 With CRL

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQeTF3dE51QnkxV3VuZjBFeVpJWGd1dlhsZ21HMzNNMk9PWUVVUTljQ2ZBdzVRTzB1a3IySDRYLWNHTnAtMzE3Y3pINGZxdlBxS0ROVEVIcWlndlA0MHRqNDNGVVFBNDNna2EyTVg1QnVVQ2ZvS09FemZwS3F3VzBLT1M4d1V4RlU?oc=5" target="_blank">FDA Slams REGENXBIO's MPS II Gene Therapy RGX-121 With CRL</a>  <font color="#6f6f6f">CGTLive®</font>

Read Full StoryMore like this
REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
PR Newswiregeneral

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNUEJKZFRKOUtDWWg5QUxwSkNuZUZ6SklzTHA4U01oTUpKTTZaUUYzaUtzc3FKNFZHVU14czJ0MUp2VWt3b2tTZG1mOEY5TUtnc2NnT1R6UEdSWVE1T29yYnRSS2kxWFB3b3Fnd0NMMTNSa2UweGtCeGE5NWxHM2RERkxfd3Q3Q3Fnb2dYU3dlLVAxb25ZZjU3UzJrSUF1M1Uxa0NZLTFKa1gtbWY1M3dMWGtYWEJOUENlaGpsSVZNTEg1MXlSMXhCLUdIUUVtRnowX2pVdVJXR1NUYUZrMlBNUldNRQ?oc=5" target="_blank">REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
REGENXBIO stock reports 60 percent three-year eye study response
AD HOC NEWSmarkets

REGENXBIO stock reports 60 percent three-year eye study response

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNby1hRUlIVElOYzN5cWx1RmRnaTVjazREYWVNekZIYlcxczdaeHdRMjVJUEtDclA4cC1WY3V2NEJ2R2hpZTFwZGVRX2N1QmIxcVZXT2VuRTU0d3o1ZGZqS1g4VzB0alBmbEpaYXAxZUwtT29RUkgta1VKLV9uZjFPTUNqSUFmMmRoUXBFWW53NWRGTm5iYUNDNElxZXZvaG9NT1pycFN3dkdkblRQcTFYT0xnbHNhZWZjdVlSNF9vM1Q?oc=5" target="_blank">REGENXBIO stock reports 60 percent three-year eye study response</a>  <font color="#6f6f6f">AD HOC NEWS</font>

Read Full StoryMore like this
Five patients had spine MRI findings; FDA put the gene therapy on hold
Stock Titangeneral

Five patients had spine MRI findings; FDA put the gene therapy on hold

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOOEFyNE8yVGptc3VQakxVcThsLTNKTWpEVnFGTzBMXzl6WmJfUXU2RGtvcEV4OGlseS1iOVQxZHF3LXJCd2hublBTdkNJNnRiUmlUQUlHdFNsWk16c25sb3B2TnR4N04yUnM5eXlDeUdhMFRWMjQyb2ZIWWtfOXYzZHdHb3BzU1ZIbGNRYUZqMjgyWFpoTEhDdW83b2I2M0hyUmVBM1B4MVlOLTdBXzQ3LQ?oc=5" target="_blank">Five patients had spine MRI findings; FDA put the gene therapy on hold</a>  <font color="#6f6f6f">Stock Titan</font>

Read Full StoryMore like this
REGENXBIO (RGNX) grants $550K equity to new board hire
Stock Titangeneral

REGENXBIO (RGNX) grants $550K equity to new board hire

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPWlVpbHNTQXBOX3U5dlFpelgtRHE3blQzOFZBZVNzQ0dMeFJRUmMwZER6dlRNdFp4XzRCY3dDYURPd1RKazRNVzBTbVRPWHJLcE9yMG5OeG11WlVZSVpxd0kxNjMtaUhRRU9DLXhSdXdPV21ROE9ibzZFMnRJdzNSQWFSM0JDVkFrV1NfdFY5NGQxR2M2N2lHc2ttdm1QdkE5dDZadA?oc=5" target="_blank">REGENXBIO (RGNX) grants $550K equity to new board hire</a>  <font color="#6f6f6f">Stock Titan</font>

Read Full StoryMore like this
REGENXBIO doses first patient in eye-disease gene therapy trial
Stock Titangeneral

REGENXBIO doses first patient in eye-disease gene therapy trial

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNM1Z4dUh0U1R1MmNaYW9zd3VlVWF6QjVQb3BsVGVzMG1wa19UTTBISk9LaU4ycE5halJsZ011WTE2dmQ2LWtyQkpweXpKOWpMYzZkeUFvVVRnSlA2TDRnT19hajJsZnplaUh3eUFxcHlNZWY5RmIxQWFKeWp2ZklucEdmdjczanVlSGVtRmJvVWcyTWZTaWlJY1JZMHczT182Vlk5ZWtvZW9TNDdzSFBpSXlpUV84SFBvY2F3aXBMYw?oc=5" target="_blank">REGENXBIO doses first patient in eye-disease gene therapy trial</a>  <font color="#6f6f6f">Stock Titan</font>

Read Full StoryMore like this
REGENXBIO gets FDA path to resubmit NAVSUNLI for MPS II
Stock Titanworld

REGENXBIO gets FDA path to resubmit NAVSUNLI for MPS II

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxOcGxveGdJWUp6RGNwS1hRemRZaTdSNmViM0RDMF90NHlSWWxOZ0I3a1dFdlJEWFNpelZyWm1NdTVDd2lEaVNwWTlyTk5DeTd6STJCcERUNlAzS0JGcFpCejlrcC1mbVNuVlhrcnZPRFo0UFlWWU1SeHN6NHUxMDB4ZGpqQU5MdWE4U2hqSWdNNWN2TzdiSl9xUUxMSTRKS2czNWFfRExjTFVuT2EtWnlocUlDTQ?oc=5" target="_blank">REGENXBIO gets FDA path to resubmit NAVSUNLI for MPS II</a>  <font color="#6f6f6f">Stock Titan</font>

Read Full StoryMore like this
REGENXBIO reports data from trial of Mucopolysaccharidosis Type I therapy
Clinical Trials Arenageneral

REGENXBIO reports data from trial of Mucopolysaccharidosis Type I therapy

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQVk5uMjFnOWdNcl9DTWNaUEtVS0tnV3lRODFrRWViS0lySXlfSFlJby1QZ2dDYWpiSWxvc0FzWFJlRnQyU3dnYXRWcFYyTHR5VDRNMWdfRF92WUptVTZCYVJ2RFBnZlVObnJFQXllUl93NndXWUM1VDhueXJoNEQxVFd5N3RiTDhZaWRfankwZkM4UQ?oc=5" target="_blank">REGENXBIO reports data from trial of Mucopolysaccharidosis Type I therapy</a>  <font color="#6f6f6f">Clinical Trials Arena</font>

Read Full StoryMore like this
Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call
Yahoo Financegeneral

Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOM2NzY2k1Z200UlRMbXBwV2lvU0VtZk9wbkFHVktKdF9uc3RyMWdQV2FCZ0l3X1VOcWM0NnBWbHZPRFJ2cnBnZmRsOEZKNk0wcVFZM3JVN1hqRmw1SlNTNjYzd0xGXzV4clRfY2dZczAwN3V4MmNLdUg5V0RtWEdiVTdQS0g5SnA1RWVMZUdXUXI0dWoyLWY2Q2NR?oc=5" target="_blank">Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
REGENXBIO slumps after serious side effects mar Duchenne gene therapy results
BioSpacegeneral

REGENXBIO slumps after serious side effects mar Duchenne gene therapy results

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQcjhQVlFjdW95WWM1bF8xdmhNYlJ3U1hUaERqLTZycmx2cERWS1J4WTctb1NwWGtZbjJaVnYyaTUzMDMyLVNuWWRCOVdVUHFJUkEzb2oyVXhmdlJfeTlXcVNDdVBlSVhuMWd0U01MbzRYWlJKNUozOU1QOUU5N0JtemNDUDJWU09hcmM2MnRwaUtHLXNwUUptNXFjTFNsckJhQ2ZNM04tYmtiV0lLWW5WNnhqUUtEX1V3MzhUanlB?oc=5" target="_blank">REGENXBIO slumps after serious side effects mar Duchenne gene therapy results</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
PR Newswireworld

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPbVhOamlpLTMxcXJQemVtbU1KWGlUWXh1MXFjMnlNeHgtUXpoVEt5ZzU4Z1VSMkpENkhlUlBqM3JETHdYWWx2Rml3cmdXWWZ3MTNNaDR4SHljOHdReGRvaGpKVmlmX2dQeU9NNkRMN1FlMW5JVnZIMHFmdzJjSkUtdTdVaGxoT0ZhckVkVzlqenFXTjRhUFpyQ0xCa3FSMDI1b3ZiT2g5REQwVkMtVGdESlowU3B3QUFqVVRz?oc=5" target="_blank">REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome
Yahoo Financeworld

Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPVTFYQWx5UDBQU3pvRHpObzR2a01reFZXZjdRc3R1Y2JKU0ZYSlRvbGE5eERvVEptcGlnU2M3REVfYXhOVnA5RE81czV6clcxamFUTEdROFUtOUxVWHdZeG0wOVUzc1Zqdm51TjZSekF1elBrQVFkVFM2RDRxR3N6ckgtODRoM2FJX2oxX25Zb3JPZ0tvVTdWaUV3TzdRdw?oc=5" target="_blank">Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
PR Newswireworld

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxNMXdtSUpMZVhPYmk5a0JnZnJTeVNnN3lRc2lMOHA5YmFHT201S2NVYS0zbGY3b3ZldDdsMm9NZ2djXzBJLWhLWWV4d3pxV3ZJVUtkQlczbUVMd0MyMVFzZl9WMjd4RjhBcS1ELW0yWkhTVWJmWkJ1TjVpYlpNV1plc2NEak91TlJyZ3FDVW5sLU9uR3cxcEdQeXFzY3k5OFpLYVFvdllHaFlOQkVSSGlfbE10WWJkeUZWMEJGSFRnZjNhWDk3Ung4UGE2UTNqVUZyS0pOTW1pRVpJcXJrV2c?oc=5" target="_blank">REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Regenxbio, Solid report data with Duchenne gene therapies
pharmaphorumgeneral

Regenxbio, Solid report data with Duchenne gene therapies

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxPMkVwNFZROXdCVGRjNUx1c2tUMHBlaFdzVElVY1N4Ty1SOU9VSmtPWTlENmdoRnFfYi1MZ1UxeVdOWDlEYkJpd1RPbDZZbmtpRnQ0OU1pQ1lSSWowa2VxMVBPR3pDaGE0YUs5YTBhakdtT25lVnFpTUNHckRpYkdEMlVSbndVdzlH?oc=5" target="_blank">Regenxbio, Solid report data with Duchenne gene therapies</a>  <font color="#6f6f6f">pharmaphorum</font>

Read Full StoryMore like this
FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial
Clinical Trials Arenageneral

FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPclNiQjdndF8wNk1UMGlSZTM0alA5TDROOGxLT0F4MDZNdVgwZFFselpibkE2Ym1RX09GU0hhZWY1TU1fYmFFcXNhNGlDekZPN2JPY2lIRWtzWXVTTkNnSVlhdmJna2hMYzdaRGhlRG9TWVZJUlhqSW1RS3ZlZkNoQ0xCS3oyS0tVYnNNUA?oc=5" target="_blank">FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial</a>  <font color="#6f6f6f">Clinical Trials Arena</font>

Read Full StoryMore like this
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
PR Newswireworld

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxOYmc4WE5BLWdyRTZGWFJUODVaY0Q2U09aMEFjRWNQV2VqZ3FfSklxeDdUSTJNZWpVbm05ME1QdVRhVFFqYlJJcnl6eDkwaEtfUmpieGFfcHFUN2ZEUmlPVEszRUt6UWFIWlB2UEppVEdrQV9GQ0lUcy1sMUVDNFMxYXBpUEhobzRoS1hXV1RnN0JzWEN6OTcyNUVrTnJsT0N5dUUtT1JKN2lObjIyV2d0dXdUYTFpT1ItbDhRcVA2Sk5JaW1ManFsZFU1dC1uSkVZaVBNN1VqTGl3dmFU?oc=5" target="_blank">REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
H.C. Wainwright reiterates Regenxbio stock rating on diabetic retinopathy data
Investing.comtech

H.C. Wainwright reiterates Regenxbio stock rating on diabetic retinopathy data

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQZ1VZTjd0SnBiUzYtUWNwS0J2aWFLbzlXTmtaYzBhaFhYMXZ2T2g5VVNwMWVUNFRlb2M0WmpJalJEM1RhM3ZyRy02Wk1PcUhSYW9TWUQ3dGtmS295REtBR2xKWWlqaWN4cGJBVUlCQm8zUEEyc0RPRlBHUHJFbkVtMDBCVUFtU2NSdDlRdTZtMVBqOG5ncV9zZDBKQ1Q5RjZTWk1UXzM1dW85TFFfb2JwYXFxNnpIczBNVnkwckRiX1BfX2VnR2YtOXduaDJtX3BEakE?oc=5" target="_blank">H.C. Wainwright reiterates Regenxbio stock rating on diabetic retinopathy data</a>  <font color="#6f6f6f">Investing.com</font>

Read Full StoryMore like this
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment
BioSpaceworld

Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPSm15T25WeEozX1hFcVVpdUFBRXowajZqRnhwM0R5MVd3cVNTU1VEVlBKS1JubUJ1YzE1SXVTeHVURm1LeXFTbUhqY2F5aF9GNjFoUWJRTGxUQ3JLQUNFMTlJMlRKQjNFV1NCc2RxQ2F2OFN5UGdJNGtqMmFRVThfLXlzM0ZZNmRXNVY1NVR0NnhIVFBGRk12bTdFNURSYURDaGNNVUtndlVLQ2lyQU5pNFQxcGlmdkpKWEJKRA?oc=5" target="_blank">Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
"REGENXBIO Reports Second" — Live Google News Trends & Headlines